Table 2.

Potential savings: episode and total costs by type of treatment in the last two months for different utilisation assumptions, USD 2013

	Top-down; mean (range)	Bottom-up; mean (range)
EPISODE COSTS
Facility-DOT
45 % continuation phase	283.7 (108.5–410.5)	160.6 (82.7–373.3)
Patient utilisation	286.9 (109.6–415.2)	162.3 (83.5–377.6)
SAT
45 % continuation phase	115.1 (38.9–470.8)	61.6 (20.8–168.5)
Patient utilisation	127.7 (42.6–525.0)	68.0 (22.4–187.6)
Community-DOT
45 % continuation phase	441.5 (397.6–485.6)	169.8 (162.8–176.8)
Patient utilisation	463.8 (417.6–510.1)	178.1 (170.8–185.6)
Average total costs by treatment type
Facility-DOT
45 % continuation phase	16,834 (2,824–24,631)	10,083 (848–18,260)
Patient utilisation	17,024 (2,855–24,911)	10,194 (857–18,467)
SAT
45 % continuation phase	2,021 (65.6–4,701)	1,287 (55.4–3,562)
Patient utilisation	2,227 (72.5–5,157)	1,407 (61.1–3,884)
Community-DOT
45 % continuation phase	43,660 (23,308–64,012)	17,351 (8,486–26,216)
Patient utilisation	45,856 (24,486–67,226)	18,203 (8,907–27,500)
Average total costs per facility
45 % continuation phase	24,221 (4,010–64,954)	12,824 (1,316–26,551)
Patient utilisation	25,018 (4,159–68,276)	13,204 (1358–27873)

DOT directly observed therapy; SAT self-administered therapy

Utilisation assumptions: 1) 45 % continuation phase. In this scenario we calculated the costs in the last two months of treatment as a proportion of the continuation phase costs; 2) Patient utilisation. In this alternative scenario, costs in the last two months of treatment are calculated using the reported number of visits by patients interviewed